Search

Search results

375 results found

IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.

Kimball, Alexa B, Christian Loesche, Errol P Prens, Falk G Bechara, Jamie Weisman, Izabela Rozenberg, Philip Jarvis, et al. 2022. “IL-17A Is a Pertinent Therapeutic Target for Moderate-to-Severe Hidradenitis Suppurativa: Combined Results from a Pre-Clinical and Phase II Proof-of-Concept Study.”. Experimental Dermatology 31 (10): 1522-32.